Bifogade filer
FluoGuide Q2 2022 fv (1)
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
In H1 2022, FluoGuide reached a major milestone in the clinical development showing that FG001 is very well tolerated and FG001 illuminates aggressive brain cancer. This has significantly de-risked FG001.
FluoGuide had no revenue for the period and therefore posted a net loss of KDKK -9,702 for the period 1 January to 30 June 2022 (-7,778). The financial result for the period is in line with the Company's development plans. It is the Board’s opinion that FluoGuide, unlike many other life science companies, may have a comparatively short time from the initiation of product development to revenue generation.
| Summary | Q2 22 | Q2 21 | H1 22 | H1 21 | 2021 |
| 01-apr-22 | 01-apr-21 | 01-jan-22 | 01-jan-21 | 01-jan-21 | |
| (KDKK) | 30-jun-22 | 30-jun-21 | 30-jun-22 | 30-jun-21 | 31-dec-21 |
| Net Revenue | |||||
| Operating result | -7.514 | -6.034 | -12.942 | -10.233 | -28.809 |
| Net result | -5.749 | -4.437 | -9.702 | -7.778 | -23.770 |
| Cash and bank | 39.136 | 49.712 | 39.136 | 49.712 | 46.758 |
| Result per share (DKK) *) | -0,50 | -0,40 | -0,83 | -0,72 | -2,15 |
| Solidity (%) **) | 92% | 82% | 92% | 82% | 73% |
| Avarage shares for the period | 11.435.000 | 10.963.803 | 11.625.798 | 10.748.113 | 11.036.155 |
a *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. .
**) Solidity: Total equity divided by total capital and liability.
HIGHLIGHTS DURING Q2
- FluoGuide announces positive top line result from the first part of the ongoing clinical phase I/II trial testing the safety and performance of FG001 in lightening up aggressive brain cancer
- Presentation of clinical data on FG001 at the 68th Scandinavian Neurosurgical Society Congress held 14-16 May 2022 in Bergen, Norway
- FluoGuide published interim report for the period January – March 2022 on 31 May 2022
HIGHLIGHTS AFTER Q2HI
- Investor presentations in second half of 2022
- A publication of clinical data that shows uPAR is highly expressed Head and Neck cancer
- Submitted CTA to initiate phase IIa in Head and Neck cancer
Update on FluoGuide clinical programs
Morten Albrechtsen, CEO says: “FluoGuide reached a major milestone in its development in H1 2022, with the exciting data from our phase I/IIa trial of FG001 in aggressive brain cancer, as it makes it significantly more likely that FG001 will become a commercial product”